Therefore, biomarkers such as NT-proBNP, hsTnT, hsTnI, anti-Apo A-I, and ox-LDL contribute significantly to the early identification of cardiovascular abnormalities and accurate cardiovascular risk stratification in RA patients. This evidence concerns the gene NPPB and rheumatoid arthritis.